CVS director receives deferred stock unit grant

CVS Health director Alecia A. Decoudreaux received a compensation-related grant of deferred stock units.

Rhea-AI Filing Summary

CVS Health director Alecia A. Decoudreaux received a compensation-related grant of deferred stock units. On May 14, 2026, she was awarded 1,447.5039 deferred stock units valued at $97.15 per unit for deferring a semi-annual director retainer under CVS Health’s 2017 Incentive Compensation Plan. Each unit will later convert into one share of common stock, to be issued in the future according to her election. Following this grant, she directly holds a total of 42,181.8314 deferred stock units. The filing shows no open-market purchases or sales, only this grant/award acquisition.

Insider Trade Summary

Grant/Award: 1,447.5039 shares

Grant/Award 1 txn

Insider DECOUDREAUX ALECIA A

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Deferred Stock Units	1,447.5039	$97.15	$141K

Holdings After Transaction: Deferred Stock Units — 42,181.8314 contracts (Direct)

Footnotes (2)

1. F1. Consists of deferred stock units issued for deferral of a semi-annual retainer in connection with the Issuer's non-employee director compensation policy, valued at the market price, pursuant to the Issuer's 2017 Incentive Compensation Plan.
2. F2. Consists of deferred stock units, each to be converted into one share of common stock and issued in the future, as elected by the Reporting Person.

Key Figures

Deferred stock units granted: 1,447.5039 units Unit valuation: $97.15 per unit Total deferred units after grant: 42,181.8314 units +2 more

5 metrics

Deferred stock units granted 1,447.5039 units Grant on May 14, 2026 as semi-annual retainer deferral

Unit valuation $97.15 per unit Market price used to value deferred stock units

Total deferred units after grant 42,181.8314 units Director’s deferred stock unit balance following transaction

Underlying common shares 1,447.5039 shares Each deferred stock unit converts into one common share

Exercise price $0.00 Conversion/exercise price of deferred stock units

Key Terms

Deferred Stock Units, non-employee director compensation policy, 2017 Incentive Compensation Plan, semi-annual retainer, +1 more

5 terms

Deferred Stock Units financial

"Consists of deferred stock units issued for deferral of a semi-annual retainer"

Deferred stock units are promises from a company to give an employee shares of stock at a future date, often after certain conditions are met or after leaving the company. They function like a form of delayed compensation, allowing employees to earn shares over time. For investors, they represent potential future ownership in the company, but do not provide immediate voting rights or dividends until the shares are actually received.

non-employee director compensation policy financial

"in connection with the Issuer's non-employee director compensation policy"

2017 Incentive Compensation Plan financial

"pursuant to the Issuer's 2017 Incentive Compensation Plan"

semi-annual retainer financial

"issued for deferral of a semi-annual retainer in connection with the Issuer's"

converted into one share of common stock financial

"each to be converted into one share of common stock and issued in the future"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did CVS (CVS) report for Alecia A. Decoudreaux?

CVS reported that director Alecia A. Decoudreaux received a grant of deferred stock units as compensation. The units reflect a semi-annual retainer she chose to defer under CVS’s 2017 Incentive Compensation Plan, rather than an open-market stock purchase or sale.

How many deferred stock units did the CVS (CVS) director receive?

Alecia A. Decoudreaux was granted 1,447.5039 deferred stock units. These units were issued in connection with the deferral of a semi-annual director retainer and are valued at the market price under CVS Health’s non-employee director compensation policy and 2017 Incentive Compensation Plan.

At what value were the new CVS (CVS) deferred stock units recorded?

The 1,447.5039 deferred stock units were valued at $97.15 per unit. This value reflects the market price used when issuing the units in exchange for deferring a semi-annual retainer under CVS Health’s non-employee director compensation policy and incentive plan.

What do the CVS (CVS) deferred stock units convert into and when?

Each deferred stock unit will convert into one share of CVS common stock. The shares will be issued in the future, at times elected by Alecia A. Decoudreaux, consistent with the company’s non-employee director deferral and incentive compensation arrangements.

What is Alecia A. Decoudreaux’s total CVS (CVS) deferred stock unit position after this grant?

After receiving 1,447.5039 additional deferred stock units, Alecia A. Decoudreaux holds 42,181.8314 deferred stock units directly. This total reflects accumulated grants under CVS Health’s non-employee director compensation programs, including the most recent semi-annual retainer deferral.

Did the CVS (CVS) Form 4 show any stock sales or open-market buys by the director?

The Form 4 shows no open-market purchases or sales by Alecia A. Decoudreaux. It reports only a grant or award acquisition of deferred stock units related to her semi-annual director retainer under CVS Health’s established compensation and deferral programs.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/15/2026 - 05:10 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

DECOUDREAUX ALECIA A

(Last) (First) (Middle)

ONE CVS DRIVE

(Street)

WOONSOCKET RHODE ISLAND 02895

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CVS HEALTH Corp [ CVS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Deferred Stock Units	$0	05/14/2026		A(1)		1,447.5039		(2)	(2)	Common Stock	1,447.5039	$97.15	42,181.8314	D

Explanation of Responses:

1. Consists of deferred stock units issued for deferral of a semi-annual retainer in connection with the Issuer's non-employee director compensation policy, valued at the market price, pursuant to the Issuer's 2017 Incentive Compensation Plan.

2. Consists of deferred stock units, each to be converted into one share of common stock and issued in the future, as elected by the Reporting Person.

	/s/ Alecia A. DeCoudreaux	05/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)